Latest Ratios: P/E Ratio -16.9x · EV/EBITDA N/A · ROE -39.7%. (1999–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.1B | $418M | $236M | $338M | $317M | $574M | $379M | $485M | $703M | $1.0B | $1.4B |
| Enterprise Value | $1.1B | $445M | $278M | $422M | $325M | $512M | $266M | $695M | $788M | $975M | $1.2B |
| P/E Ratio → | -16.93 | — | — | — | — | — | — | 3.74 | — | — | — |
| P/S Ratio | 21.14 | 8.38 | 7.60 | 281.00 | 2277.34 | 1925.73 | 15.80 | 1.50 | 11.12 | 11.51 | 17.24 |
| P/B Ratio | 8.00 | 3.88 | 1.62 | 3.63 | 2.70 | 5.05 | 2.42 | 4.14 | — | 19.96 | 9.13 |
| P/FCF | — | — | — | — | — | — | — | 4.26 | — | — | — |
| P/OCF | — | — | — | — | — | — | — | 4.26 | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 8.94 | 8.95 | 350.44 | 2341.72 | 1718.40 | 11.07 | 2.16 | 12.46 | 10.79 | 14.30 |
| EV / EBITDA | — | — | — | — | — | — | — | 4.79 | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | 4.80 | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | 6.11 | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 99.4% | 99.4% | 98.0% | -4798.0% | -37681.3% | -18371.8% | 92.0% | 99.0% | 96.1% | 97.9% | -96.8% |
| Operating Margin | -98.2% | -98.2% | -634.2% | -14265.0% | -72489.2% | -29224.8% | -199.2% | 43.9% | -163.4% | -151.3% | -164.6% |
| Net Profit Margin | -101.1% | -101.1% | -644.8% | -14710.9% | -73341.0% | -29449.0% | -244.1% | 40.4% | -190.7% | -142.9% | -169.7% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -39.7% | -39.7% | -167.7% | -168.5% | -88.4% | -65.0% | -42.8% | 111.1% | — | -123.2% | -63.8% |
| ROA | -20.8% | -20.8% | -75.9% | -83.6% | -61.6% | -51.5% | -18.8% | 37.1% | -33.5% | -28.3% | -25.0% |
| ROIC | -22.7% | -22.7% | -81.1% | -85.1% | -85.0% | -137.9% | -19.3% | 32.4% | — | — | — |
| ROCE | -23.4% | -23.4% | -87.4% | -93.1% | -70.5% | -64.1% | -18.8% | 47.2% | -36.9% | -43.9% | -32.5% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.58 | 0.58 | 0.74 | 1.14 | 0.47 | 0.02 | 0.08 | 2.11 | — | 4.72 | 0.64 |
| Debt / EBITDA | — | — | — | — | — | — | — | 1.70 | — | — | — |
| Net Debt / Equity | — | 0.26 | 0.29 | 0.90 | 0.08 | -0.54 | -0.73 | 1.80 | — | -1.25 | -1.56 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | 1.45 | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | 1.85 | — | — | — |
| Interest Coverage | -5.87 | -5.87 | -11.86 | -13.00 | -36.14 | -108.59 | -3.03 | 7.00 | -4.80 | -18.42 | -19.02 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.88 | 4.88 | 5.44 | 5.60 | 6.08 | 4.02 | 3.37 | 5.17 | 4.72 | 2.59 | 2.17 |
| Quick Ratio | 4.87 | 4.87 | 5.44 | 5.58 | 6.08 | 4.02 | 3.37 | 5.10 | 4.59 | 2.58 | 2.17 |
| Cash Ratio | 4.61 | 4.61 | 5.26 | 5.39 | 5.97 | 3.92 | 3.25 | 4.16 | 4.36 | 2.50 | 2.10 |
| Asset Turnover | — | 0.27 | 0.10 | 0.01 | 0.00 | 0.00 | 0.12 | 0.77 | 0.22 | 0.21 | 0.18 |
| Inventory Turnover | 0.98 | 0.98 | 2.67 | 154.78 | — | — | — | 0.76 | 0.53 | 0.97 | — |
| Days Sales Outstanding | — | 17.47 | 40.79 | 306.19 | 73.53 | 17.15 | 6.01 | 64.07 | 34.21 | 19.50 | 32.81 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | 26.7% | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | 23.5% | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.7% | 0.2% | 0.3% | 0.5% | 0.3% | 0.2% | 0.1% | 0.2% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.7% | 0.2% | 0.3% | 0.5% | 0.3% | 0.2% | 0.1% | 0.2% | 0.0% |
| Shares Outstanding | — | $363M | $320M | $221M | $166M | $146M | $111M | $117M | $106M | $105M | $104M |
Imminent liquidity shortfall risk
According to current market data, Lexicon trades at a price-to-sales multiple of 22.74, which appears to price in significant future commercial success despite the company's negative TTM P/E of -18.21 and the ongoing uncertainty surrounding the INPEFA launch trajectory relative to established cardiovascular market incumbents.
The elevated P/S ratio suggests that investors are assigning value to the pipeline potential rather than current commercial output. This valuation appears disconnected from the company's immediate financial reality, implying that the market may be pricing in a binary outcome regarding the success of the heart failure launch or a potential acquisition.
Based on reported financial statements, Lexicon's ROIC has consistently remained in negative territory, with a recent figure of -0.4% in 2026Q1, indicating that the company is currently destroying shareholder value as it attempts to scale its commercial operations without achieving a sustainable return on invested capital.
The persistent negative ROIC trend highlights the difficulty of transitioning from a research-focused entity to a commercial-stage company. Without a significant increase in net product sales to offset the high fixed costs of the sales force, the company appears unlikely to achieve positive capital returns in the near term.
As reported in recent quarterly filings, Lexicon's cash conversion cycle has exhibited extreme volatility, swinging from -2271 days in 2026Q1 to -43087 days in 2025Q3, which suggests that the company's management of inventory and accounts payable is currently highly unstable and lacks operational predictability.
The erratic nature of these efficiency metrics reflects the challenges of a nascent product launch where inventory stocking and wholesaler dynamics distort standard working capital ratios. Investors should monitor whether these figures stabilize as the commercial launch matures and the company establishes a more consistent rhythm with its distribution partners.
According to recent SEC filings, Lexicon's current ratio has declined from 18.79 in 2026Q1 to lower levels in previous periods, yet the absolute cash balance of $34.3M remains dangerously thin relative to the company's ongoing quarterly operating losses and the high costs of maintaining a specialized sales force.
The liquidity position appears vulnerable, as the company's ability to fund operations without further dilutive financing is increasingly constrained. This suggests that the current cash runway may be insufficient to support the long-term commercialization of INPEFA, warranting close monitoring of potential capital-raising activities.
Based on the provided financial data, the most commonly misapplied metric for Lexicon is the gross margin, which frequently exceeds 99%, as it obscures the massive underlying operating losses and the high commercialization costs that define the company's current financial profile as a small-cap biotech.
While high gross margins are typical for small-molecule drug manufacturers, they provide a false sense of security regarding the company's earning power. Analysts should instead focus on the operating margin and the cash burn rate, which more accurately reflect the company's struggle to achieve scale and operational sustainability.
Includes 30+ ratios · 27 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying LXRX stock.
Lexicon Pharmaceuticals, Inc.'s current P/E ratio is -16.9x. The historical average is 3.7x.
Lexicon Pharmaceuticals, Inc.'s return on equity (ROE) is -39.7%. The historical average is -52.8%.
Based on historical data, Lexicon Pharmaceuticals, Inc. is trading at a P/E of -16.9x. Compare with industry peers and growth rates for a complete picture.
Lexicon Pharmaceuticals, Inc. has 99.4% gross margin and -98.2% operating margin.